Eurekabio, an emerging manufacturing supplies platform for Cell and Gene Therapy (CGT) in China, announced that the company has completed a Series B financing led by Eight Roads, with participation from its sister fund F-Prime Capital. JiuFeiTe, Juke Investment, and existing investor also participated in this round.
Founded in 2014, Eurekabio provides comprehensive solutions for the cell and gene therapy (CGT) industry through its strong interdisciplinary expertise and technological innovations.
The funding will be used to further expand the pipeline and commercial footprint of CGT manufacturing equipment/ consumables. Eurekabio will also further strengthen the R&D of its EuLV platform, a large-scale viral vector production technology based on a stable cell line, bringing more core technologies and products to the CGT manufacturing and further facilitating cost reduction and efficiency improvement for the CGT industry.
Dr. Lei Shi, Partner of Eight Roads China said: “Eight Roads is committed to supporting platform companies with global leading technology and indigenous innovation capability. With its unique cross-disciplinary strengths and deep experience in this field, Eurekabio has won the recognition of leading global and domestic companies in the field of the CGT manufacturing industry. We look forward to working with the company and supporting it to grow into a global leading manufacturing supplies platform for CGT.”